tailieunhanh - Báo cáo y học: "A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. | Moore et al. Cost Effectiveness and Resource Allocation 2010 8 7 http content 8 1 7 COST EFFECTIVENESS AND RESOURCE ALLOCATION RESEARCH Open Access A Health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK Lee Moore 1 Vanessa Remy2 Monique Martin 1 Maud Beillat2 and Alistair McGuire3 Abstract Background A live-attenuated vaccine aimed at preventing herpes zoster HZ and its main complication postherpetic neuralgia PHN is available in Europe for immunocompetent adults aged 50 years and more. The study objective is to assess the cost effectiveness of a vaccination program for this population in the UK. Methods A state-transition Markov model has been developed to simulate the natural history of HZ and PHN and to estimate the lifetime effects of vaccination in the UK. Several health states are defined including good health HZ PHN and death. HZ and PHN health states are further divided to reflect pain severity. Results The model predicts that a vaccination strategy for those aged over 50 years would lead to an incremental cost-effectiveness ratio of 13 077 per QALY gained from the NHS perspective when compared to the current strategy of no vaccination. Age-group analyses show that the lowest ICERs 10 984 and 10 275 for NHS are observed when vaccinating people between 60-64 and 65-69 years of age. Sensitivity analyses showed that results are sensitive to the duration of vaccine protection discount rate utility decrements and pain severity split used. Conclusions Using the commonly accepted threshold of 30 000 per QALY gained in the UK most scenarios of vaccination programmes preventing HZ and PHN including the potential use of a repeat dose may be considered cost-effective by the NHS especially within the 60 to 69 age-groups. Background In our aging society diseases whose prevalence rises with age are of increasing significance. The varicella zoster virus VZV causes chickenpox as

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.